重大血管手术围术期抗血栓管理:竞争性血栓与出血风险的叙述性综述
该叙述性综述综合评估了重大血管手术围术期抗血栓策略的证据,发现证据以观察性研究为主,缺乏手术特异性随机对照试验。颈动脉内膜切除术研究最多,但双联抗血小板治疗对缺血结局的影响不一致,出血风险一致增加。现有证据不支持常规升级围术期抗血栓治疗,结论应视为假设生成性。
要点
- 证据以观察性研究为主,无手术特异性随机对照试验直接评估围术期抗血栓策略。
- 颈动脉内膜切除术中双联抗血小板治疗对缺血结局影响不一致,但出血风险一致增加。
- 膝下人工血管旁路中直接口服抗凝药可能优于华法林,但缺乏随机或外部验证。
核心结论
- 当前证据不支持对血管手术围术期抗血栓管理做出明确的、手术特异性推荐,应视为假设生成性。
- 缺乏随机、手术靶向试验是该领域的主要局限。
研究设计与样本
- 叙述性文献综述,聚焦随机对照试验、大型观察性研究和主要登记数据库。
- 证据按手术类型、数据来源和地理来源分层。
主要发现
- 证据基础绝大多数为观察性,主要依赖北美登记数据,尤其是血管质量倡议(VQI)。
- 颈动脉内膜切除术中双联抗血小板治疗对缺血结局的影响不一致:VQI 125,469例患者 RR 0.80;国际汇总分析47,411例患者 OR 0.87;出血风险一致增加。
- 膝下人工血管旁路中,观察性数据提示直接口服抗凝药 compared with 华法林可能关联改善结局,但缺乏随机或外部验证确认。
- WAVE试验是外周动脉疾病中唯一评估抗血栓强化的大型随机研究,显示出血增加但主要心血管事件未减少。
- 跨血管手术,无随机证据支持常规升级围术期抗血栓治疗。
临床怎么用
- 临床决策需个体化权衡血栓风险、出血风险和手术因素,但结构化框架尚需正式验证。
- 不应常规升级围术期抗血栓治疗,尤其缺乏随机证据支持。
- 高风险手术如重大截肢需优先开展高质量前瞻性研究以明确风险-获益平衡。
局限性
- 证据以观察性研究为主,缺乏手术特异性随机对照试验。
- 数据主要来自北美登记,地理代表性有限。
- 直接口服抗凝药用于膝下旁路的信号缺乏随机或外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To critically synthesize the available evidence on perioperative antithrombotic strategies across major vascular surgical procedures, with emphasis on study design, level of evidence, and clinical applicability, and to identify persistent evidence gaps. METHODS: A narrative review of the literature was performed, focusing on randomized controlled trials, large observational studies, and major registry datasets evaluating perioperative antithrombotic strategies in vascular surgery. Evidence was stratified according to procedure type, data source, and geographic origin. RESULTS: The evidence base is overwhelmingly observational, with predominant reliance on North American registry data, particularly the Vascular Quality Initiative (VQI). No procedure-specific randomized controlled trial has directly evaluated perioperative antithrombotic strategies in major vascular surgery. Carotid endarterectomy remains the most extensively studied procedure, although the effect of dual antiplatelet therapy on ischemic outcomes is inconsistent across large datasets (e.g., VQI RR 0.80 in 125,469 patients; pooled international analyses OR 0.87 in 47,411 patients), while an increased bleeding risk is consistently reported across studies. For infrageniculate prosthetic bypass, observational data suggest a potential association between direct oral anticoagulants and improved outcomes compared with warfarin; however, this signal lacks randomized or externally validated confirmation. The WAVE trial, the only large randomized study in peripheral arterial disease evaluating antithrombotic intensification, demonstrated increased bleeding without reduction in major cardiovascular events. Across vascular procedures, no randomized evidence supports routine escalation of perioperative antithrombotic therapy. CONCLUSION: Current evidence does not support definitive, procedure-specific recommendations for perioperative antithrombotic management in vascular surgery and should be considered hypothesis-generating. The absence of randomized, procedure-targeted trials represents a major limitation in the field. Future research should prioritize high-quality prospective studies to better define risk-benefit balance, particularly in high-risk procedures such as major amputation. A structured framework incorporating thrombotic risk, bleeding risk, and procedural factors may support individualized decision-making but requires formal validation.
引用
- Galassi L, Facchinetti F, Ravini ML, et al. Perioperative Antithrombotic Management in Major Vascular Surgery: A Narrative Review of Competing Thrombotic and Hemorrhagic Risks. Ann Vasc Surg. 2026. PMID: 42442532. doi:10.1016/j.avsg.2026.06.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。